Oncotelic Therapeutics (OTCQB: OTLC) has announced a strategic partnership with TechForce Robotics to advance the commercialization of its proprietary AI-enabled, GMP-compliant robotics platform designed for pharmaceutical manufacturing and regulated environments. The collaboration combines Oncotelic's artificial intelligence capabilities with TechForce's robotics and manufacturing expertise to create an integrated system that automates material handling, enables real-time monitoring, and streamlines compliance workflows. The companies have entered into a joint development, manufacturing and licensing agreement, with plans for scalable deployment to address the increasing demand for intelligent, compliant automation solutions in the pharmaceutical industry.
The platform, known as PDAO, leverages Oncotelic's proprietary AI to enhance operational efficiency and regulatory adherence in drug manufacturing. By integrating robotics with advanced analytics, the system aims to reduce human error, improve traceability, and accelerate production timelines. This partnership positions Oncotelic to tap into the rapidly growing market for automation in life sciences, where regulatory compliance and precision are paramount. The collaboration is expected to accelerate the path to commercialization, with both companies contributing their respective strengths to refine and scale the technology.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company's pipeline includes innovative late-stage therapeutic candidates, and it benefits from the extensive patent portfolio of its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, Oncotelic also licenses and co-develops drug candidates through joint ventures, including a 45% stake in GMP Bio, which advances complementary therapies.
The partnership with TechForce Robotics marks a strategic expansion of Oncotelic's capabilities beyond drug development into manufacturing automation. This move aligns with broader industry trends toward digitalization and robotics in pharmaceutical production, driven by the need for efficiency, quality, and compliance. The companies plan to initially target the GMP manufacturing sector, with potential applications in other regulated industries. By combining AI and robotics, the platform offers a comprehensive solution for automated material handling, real-time monitoring, and compliance management, addressing key pain points in pharmaceutical manufacturing.
For more information, visit the press release at https://ibn.fm/nvCXn. Updates on Oncotelic Therapeutics are available in the company's newsroom at https://ibn.fm/OTLC.
